Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Current Deferred Revenue (2019 - 2025)

Avidity Biosciences' Current Deferred Revenue history spans 7 years, with the latest figure at $50.3 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 139.82% year-over-year to $50.3 million; the TTM value through Dec 2025 reached $50.3 million, up 139.82%, while the annual FY2025 figure was $50.3 million, 139.82% up from the prior year.
  • Current Deferred Revenue reached $50.3 million in Q4 2025 per RNA's latest filing, down from $51.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $69.3 million in Q4 2023 to a low of $2.0 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $27.6 million, with a median of $8.6 million recorded in 2021.
  • The largest YoY upside for Current Deferred Revenue was 3046.39% in 2024 against a maximum downside of 69.7% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $11.1 million in 2021, then tumbled by 44.41% to $6.2 million in 2022, then surged by 1021.67% to $69.3 million in 2023, then tumbled by 69.7% to $21.0 million in 2024, then soared by 139.82% to $50.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Current Deferred Revenue are $50.3 million (Q4 2025), $51.2 million (Q3 2025), and $53.5 million (Q2 2025).